Glutathione Stimulates Sulfated Estrogen Transport by Multidrug Resistance Protein 1*

Yue-Ming QianDagger , Wen-Chao Song§, Hengran CuiDagger , Susan P. C. ColeDagger , and Roger G. DeeleyDagger ||

From the Dagger  Cancer Research Laboratories, Queen's University, Kingston, Ontario, Canada K7L 3N6 and the § Center for Experimental Therapeutics and Department of Pharmacology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104

Received for publication, September 8, 2000, and in revised form, November 30, 2000



    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Multidrug resistance protein 1 (MRP1) is an ATP-binding cassette (ABC) transporter that transports a range of hydrophobic xenobiotics, as well as relatively hydrophilic organic anion conjugates. The protein is present at high levels in testicular Leydig and Sertoli cells. Studies with knockout mice suggest that MRP1 may protect germ cells from exposure to some cytotoxic xenobiotics, but potential endobiotic substrates in this organ have not been identified. Previously, we have shown certain D-ring, but not A-ring, estrogen glucuronides can act as competitive inhibitors of MRP1 mediated transport, suggesting that they are potential substrates for the protein. In the case of 17beta -estradiol-17beta -D-glucuronide, this has been confirmed by direct transport studies. The Leydig cell is the major site of estrogen conjugation in the testis. However, the principal products of conjugation are A-ring estrogen sulfates, which are then effluxed from the cell by an unknown transporter. To determine whether MRP1/mrp1 could fulfill this function, we used membrane vesicles from MRP1-transfected HeLa cells to assess this possibility. We found that estradiol and estrone 3-sulfate alone were poor competitors of MRP1-mediated transport of the cysteinyl leukotriene, leukotriene C4. However, in the presence of reduced glutathione (GSH), their inhibitory potency was markedly increased. Direct transport studies using [3H]estrone 3-sulfate confirmed that the conjugated estrogen could be efficiently transported (Km = 0.73 µM, Vmax = 440 pmol mg-1 protein min-1), but only in the presence of either GSH or the nonreducing alkyl derivative, S-methyl GSH. In contrast to previous studies using vincristine as a substrate, we detected no reciprocal increase in MRP1-mediated GSH transport. These results provide the first example of GSH-stimulated, MRP1-mediated transport of a potential endogenous substrate and expand the range of MRP1 substrates whose transport is stimulated by GSH to include certain hydrophilic conjugated endobiotics, in addition to previously identified hydrophobic xenobiotics.



    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Human multidrug resistance protein (MRP)1 1 is a member of the ATP-binding cassette superfamily of transmembrane transporters, which was originally discovered by virtue of its association with drug resistance in tumor cells (1). It is now also known to be a primary active transporter of many conjugated organic anions (2). The first substrate shown to be actively transported by MRP1 using inside-out membrane vesicles was the glutathione-conjugated leukotriene, LTC4 (3, 4). Since then, the spectrum of molecules transported by MRP1 has been extended to include many other GSH conjugates, as well as several glucuronate and sulfate conjugates (5, 6). A number of unconjugated amphiphilic anions have also been demonstrated to be substrates for MRP1 (7). However, using an in vitro membrane vesicle system unmodified forms of the natural product drugs to which MRP1 confers resistance are not directly transported by this protein, although primary active transport of some of them has been observed in the presence of reduced glutathione (GSH) (8-11). Potential endogenous substrates of MRP1 that show a similar dependence on the presence of GSH have not been identified, although it has been observed that the intracellular levels of GSH are reduced in some drug selected and transfected cells overexpressing MRP1 in the absence of an exogenous substrate (12-14). In addition, GSH levels are elevated in some tissues in mrp1-/- mice (15). Whether this is attributable to the efflux of GSH in association with transport of endogenous compounds has not been established.

MRP1/mrp1 is highly expressed in the sex hormone-producing Leydig cells of the human and mouse testis (16, 17), as well as in Sertoli cells of the mouse (17). Both of these cell types have high levels of GSH S-transferase activity (18, 19) and are thought to contribute to detoxification in the testis by the formation of GS conjugates, which may be substrates for MRP1 or related transporters. Studies of mrp1-/- mice have already provided evidence that testicular mrp1 protects the local tissue against drug-induced damage (17). Thus, the testes of mrp1-deficient mice treated with the anticancer drug, etoposide phosphate, showed aberrant spermatogenesis with no sign of meiotic divisions and an increased number of prematurely released round germ cells. In contrast, the same treatment of the wild-type mice produced only a partially distorted spermatogenesis and meiotic divisions still occurred.

In addition to a protective role with respect to xenobiotic exposure, the relatively high levels of MRP1 in Leydig cells may also serve to protect the testis from the potential feminizing effects of endogenously produced estrogen conjugates. Estrogen is synthesized in the testis and is required for normal testicular function, as revealed by studies of mice in which the estrogen receptor alpha  or P450 aromatase genes have been disrupted (20-22). MRP1 has been shown to transport certain estrogen glucuronides but the major metabolite in Leydig cells is estrogen sulfate produced by estrogen sulfotransferase (EST) (5, 23). Using 3'-phosphoadenosine 5'-phosphosulfate as a sulfate donor, this sulfation takes place at the 3-hydroxyl group of the parent molecule, generating the more hydrophilic estrogen 3-sulfate. The relative hydrophilicity of estrogen 3-sulfate prevents its ready diffusion across the plasma membrane. Thus, it has been assumed that an export pump is involved in its efflux from the cell. Testicular expression of estrogen sulfotransferase is mainly localized in Leydig cells and is regulated by luteinizing hormone via modulation of cAMP levels (23, 24). Interestingly, the testes of 9-12-month-old est-/- mice displayed Leydig cell hypertrophy/hyperplasia, as well as seminiferous tubule disruption.2 The colocalization of MRP1 and estrogen sulfotransferase in the testis prompted us to investigate whether estrogen sulfates were also substrates of MRP1. We found that estrogen sulfates alone were very poor substrates and competed poorly for transport and binding of the high affinity MRP1 substrate LTC4. However, in the presence of GSH, their inhibitory potency was significantly increased and GSH-enhanced direct transport of [3H]estrone sulfate could be easily detected. These results provide the first examples of potential endogenous MRP1 substrates that depend on the presence of GSH for efficient transport and the first examples of conjugated endobiotics that display this type of dependence.


    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Materials-- [6,7-3H]Estrone sulfate (53 Ci mmol-1), [2,4,6,7-3H]estradiol (87.6 Ci mmol-1), and [glycine-2-3H]GSH (42 Ci mmol-1) were purchased from PerkinElmer Life Sciences; [14,15-3H]-LTC4 (38 Ci mmol-1) and fluorographic reagent Amplify® were from Amersham Pharmacia Biotech (Oakville, Ontario, Canada). Estrogen 3-sulfates, nucleotides, GSH, verapamil, S-methyl GSH, glutathione disulfide (GSSG), 2-mercaptoethanol, and DTT were purchased from Sigma. Estrogen 3-sulfates were dissolved with H2O to prepare stock solutions at 10 mM and diluted with transport buffer. The MRP1-specific murine monoclonal antibodies (mAbs) QCRL-1, QCRL-2, QCRL-3, and QCRL-4 have been described previously (25, 26).

Cell Culture-- The HeLa T5 cells transfected with the pRcCMV vector containing the MRP1 coding sequence and the HeLa C1 cells transfected with empty pRcCMV vector have been described previously (27). Both T5 and C1 were cultured in RPMI 1640 medium with 5% defined bovine calf serum and maintained in 400 µg ml-1 Geneticin (G418). HEK293 cells were grown in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum.

Membrane Vesicle Preparation and Transport Studies-- Plasma membrane vesicles were prepared as described (8). Briefly, cell pellets were covered with buffer containing 50 mM Tris-HCl, 250 mM sucrose, 0.25 mM CaCl2, and protease inhibitors and frozen at -70 °C overnight. The cells were then thawed and disrupted by N2 cavitation (10-min equilibrium at 200 p.s.i.). EDTA was added to 1 mM before centrifugation at 500 × g for 15 min to remove cell debris. To increase the yield of membrane vesicles, the resulting pellet was washed once with 5 ml of transport buffer (50 mM Tris-HCl and 250 mM sucrose, pH 7.5) and centrifuged again. The supernatants were pooled, layered over 35% (w/w) sucrose in 10 mM Tris-HCl (pH 7.5), and centrifuged at 100,000 × g for 1 h. The interface was collected in washing buffer (10 mM Tris-HCl and 25 mM sucrose) and followed by centrifugation at 100,000 × g for 30 min. The membrane pellet resuspended in transport buffer and passed 10 times through a 27.5-gauge needle for vesicle formation. The membrane vesicles were then aliquoted and stored at -70 °C until use.

ATP-dependent transport of [3H]LTC4 into the inside-out membrane vesicles was measured by a rapid filtration technique (8). In standard transport assays, 2.5 µg of membrane vesicles were used in a 25-µl reaction volume and incubated at 23 °C in the presence of 50 nM [3H]LTC4, 10 mM MgCl2, and 4 mM ATP or AMP in transport buffer. Where indicated, GSH was added to 1 mM unless otherwise stated. Uptake was stopped by rapid dilution in ice-cold transport buffer and followed by filtration through glass fiber (type A/E) filters (Gelman Sciences, Dorval, Quebec, Canada) that had been presoaked overnight at 4 °C in transport buffer. All of the data had been corrected for the amount of [3H]LTC4 that remained bound to the filter in the absence of the membrane vesicles, which was usually less than 5-10% of the total radioactivity. For kinetic analysis of LTC4 transport in the presence of estrogen sulfates and/or GSH, LTC4 was included at concentrations ranging from 16 nM to 1 µM and ATP-dependent [3H]LTC4 uptake was determined as above.

ATP-dependent uptake of [3H]estrone 3-sulfate was measured by rapid filtration as above, except that the incubation temperature was 37 °C and substrate concentration was 300 nM unless otherwise indicated. Uptake was stopped after 60 s or at the time indicated by rapid dilution in ice-cold buffer, and the reaction mixture was filtered through glass fiber filters. Where indicated, MRP1-specific mAbs were added to 10 µg ml-1 and preincubated with membrane vesicles on ice for 1 h. All data were corrected by subtracting nonspecific binding of [3H]estrone 3-sulfate to the filter, which was usually less than 5% of the total radioactivity. For kinetic analysis of GSH-enhanced estrone 3-sulfate transport in the absence or presence of LTC4, estrone 3-sulfate was included at concentrations ranging from 125 nM to 16 µM and ATP-dependent [3H]estrone 3-sulfate uptake was determined as above.

Transport of [3H] GSH into the membrane vesicles was also measured by rapid filtration as above. In a 50-µl reaction volume, 22 µg of membrane vesicle protein were incubated at 37 °C for 20 min in the presence of 100 µM [3H]GSH (80 or 288 nCi/reaction), 10 mM DTT, 10 mM MgCl2, and 4 mM ATP or AMP in transport buffer. Estrone 3-sulfate or estradiol 3-sulfate was added to several concentrations ranging from 0.2 to 20 µM. Verapamil was used a positive control for stimulation of [3H]GSH transport (28) and was added to 100 µM. All data were corrected by subtracting the amount of [3H]GSH that remained bound to the filter in the presence of 4 mM AMP, which was usually less than 5% of the total radioactivity.

Photoaffinity Labeling of MRP1 with [3H]LTC4 and Inhibition of Labeling by Estrogen Sulfates-- Membrane vesicles (75 µg of protein in 35 µl) were incubated with [3H]LTC4 (0.25 µCi, 200 nM) in the absence or presence of various concentrations of estrone 3-sulfate or estradiol 3-sulfate at room temperature for 10 min and frozen in liquid nitrogen. Samples were alternately irradiated for 30 s at 312 nm in a Stratalinker, followed by snap-freezing in liquid nitrogen, for a total of 10 min. Radiolabeled vesicles were solubilized in Laemmli's buffer and analyzed on a 7.5% gel by SDS-polyacrylamide gel electrophoresis. The gel was fixed in isopropanol:water:acetic acid (25:65:10) for 30 min and then soaked in Amplify for 15-20 min. After drying under vacuum at 80 °C, the gel was placed in close contact with x-ray film at -70 °C for 2 weeks (8).

[3H]Estradiol Sulfate Accumulation in Intact HEK Cells-- The expression vectors pCDNA3 containing mouse estrogen-sulfotransferase cDNA (pCDNA3-est) and pCEBV7 containing human MRP1 cDNA (pCEBV7-MRP1) were described previously (29, 30), and transfection was performed with FuGENETM 6 transfection reagent (Roche Molecular Biochemicals). HEK293 cells (2 × 106) were seeded into each T75 flask and transfected on the following day with a mixture of 40 µl of FuGENETM reagent and 10 µg of pCDNA3-est or together with 10 µg of pCEBV7-MRP1. After 66 h, the cells were harvested. Half of the cells were then used for steroid accumulation experiments and the other half for an EST activity assay. [3H]Estradiol sulfate accumulation was initiated by addition of [3H]estradiol to a final concentration of 500 nM to a suspension of untransfected or transfected cells (5 × 105 cells in 100 µl of serum-free DMEM) at 37 °C and stopped at 20 min by adding 1 ml of ice-cold phosphate-buffered saline. The cells were washed twice with ice-cold phosphate-buffered saline., solubilized in 200 µl of 0.5% SDS, and extracted with 400 µl of ethyl acetate. The aqueous phase was taken for liquid scintillation counting, and 3H-labeled aqueous soluble steroid accumulation was expressed as dpm/106 cells. The procedures for preparation of cytosolic proteins and EST activity assay were the same as described previously (29, 31).


    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Inhibition of MRP1-mediated LTC4 Transport by Estrogen Sulfates-- To determine whether estrogen sulfates were potential substrates for MRP1, we initially tested the ability of estrone and estradiol 3-sulfate to compete for transport of the high affinity MRP1 substrate, LTC4. Neither estrogen sulfate alone was a potent inhibitor of [3H]LTC4 uptake by vesicles prepared from MRP1-transfected HeLa T5 (HeLa-MRP) cells (Fig. 1, A and B). At lower concentrations of the conjugated estrogens (20-200 nM), a reproducible 25-50% increase in the rate of LTC4 transport was observed with significant inhibition of transport being observed when concentrations of the estrogen sulfates reached more than 20 µM. Previously, GSH has been shown to increase the inhibitory potency of some hydrophobic xenobiotics, which are themselves poor competitive inhibitors of LTC4 transport (8). However, no effect on the transport of conjugated endobiotics has been reported. We found that addition of 1 mM GSH markedly increased the inhibitory potency of the sulfated estrogens, resulting in a decrease in IC50 values from 31 and 50 µM to 0.2 and 0.3 µM, for estrone sulfate and estradiol sulfate, respectively (Fig. 1, A and B).



View larger version (26K):
[in this window]
[in a new window]
 
Fig. 1.   Effect of estrogen sulfates on ATP-dependent [3H]LTC4 transport by membrane vesicles prepared from MRP1-transfected HeLa T5 cells. Panels A and B, the rates of [3H]LTC4 uptake by vesicles were determined at a fixed substrate concentration (50 nM) but at various concentrations of estrone 3-sulfate (A) or estradiol 3-sulfate (B) (20 nM to 200 µM) for 30 s at 23 °C. The transport assays were performed in the presence of 4 mM ATP alone (open circle ) or in combination with 1 mM GSH (). Results are expressed as a percentage of the control value obtained in the absence of competitors. Data points are means (± S.E.) of triplicate determinations in a single experiment. Panels C and D, ATP-dependent [3H]LTC4 uptake by membrane vesicles was determined at various substrate concentrations (18 nM to 1 µM) in the absence (open symbols) or presence (closed symbols) of 1 mM GSH and 2 µM estrone 3-sulfate (panel C) and estradiol 3-sulfate (panel D) for 30 s at 23 °C. The inhibitions were competitive according to the Eadie-Hofstee plots since the kinetic parameters were significantly altered for only Km but not Vmax. In the absence and presence of 2 µM estrone sulfate and 1 mM GSH, the values of Km for LTC4 were 167 ± 15 nM and 910 ± 190 nM, whereas those of Vmax were 330 ± 19 pmol mg-1 min-1 and 366 ± 62 pmol mg-1 min-1, respectively. The estimated Ki value for estrone sulfate was 0.45 µM. Similarly, in the absence and presence of 2 µM estradiol sulfate and 1 mM GSH, the values of Km for LTC4 were 136 ± 10 nM and 860 ± 266 nM, whereas those of Vmax were 361 ± 16 pmol mg-1 min-1 and 276 ± 68 pmol mg-1 min-1, respectively. The estimated Ki value for estradiol sulfate was 0.38 µM. For clarity the data for the uptakes in the presence of 1 mM GSH alone or 2 µM estrogen sulfates alone were not shown, and no significant affect was observed under these conditions. Data points are the means (± S.E.) of triplicate determinations in a single experiment.

To determine whether inhibition of LTC4 transport by the estrogen sulfates was competitive, Eadie-Hofstee plots of LTC4 transport in the absence or presence of 2 µM estrogen sulfate were constructed. At this concentration, estrone sulfate alone inhibited [3H]LTC4 transport by ~10% while estradiol sulfate stimulated transport by ~25% (Fig. 1, A and B). However, in the presence of 1 mM GSH, both estrone and estradiol sulfate behaved as competitive inhibitors of [3H]LTC4 transport, with apparent Ki values of 0.45 and 0.38 µM, respectively (Fig. 1, C and D).

Attenuation of [3H]LTC4 Photolabeling of MRP1 by Estrogen Sulfates-- To determine whether inhibition of LTC4 transport was the result of direct competition for binding, we examined the ability of the conjugated estrogens to inhibit [3H]LTC4 photolabeling of MRP1 in T5 membrane vesicles in the absence or presence of GSH. GSH alone weakly inhibited photolabeling with [3H]LTC4 (Fig. 2A), decreasing labeling by 20-25% at a concentration of 1 mM. Low concentrations of estrone or estradiol sulfate alone (0.2 µM) resulted in small but reproducible increases in [3H]LTC4 photolabeling of MRP1 (Fig. 2B), while higher concentrations either decreased (20 µM) or abolished (200 µM) labeling. The enhanced photolabeling of MRP1 observed with low concentrations (0.2-2 µM) of sulfated estrogens alone was not apparent in the presence of 1 mM GSH (Fig. 2B), and [3H]LTC4 labeling was completely abolished in the presence of 1 mM GSH and 20 µM estrone sulfate or estradiol sulfate (Fig. 2B). Furthermore, the effect of GSH could be fully mimicked by a nonreducing GSH derivative, S-methyl GSH (Fig. 2C), indicating that GSH-enhanced inhibition of [3H]LTC4 labeling of MRP1 was not caused by a change in the redox state of the protein.



View larger version (28K):
[in this window]
[in a new window]
 
Fig. 2.   Photoaffinity labeling of MRP1-enriched membrane vesicles by [3H]LTC4 and inhibition of labeling by estrone 3-sulfate and estradiol 3-sulfate in the absence and presence of GSH. MRP1-enriched T5 membrane vesicles (75 µg) were incubated with [3H]LTC4 (200 nM, 0.25 µCi) alone or in the presence of various concentrations of competitors at 22 °C for 10 min. Samples were irradiated at 312 nm prior to being subjected to SDS-polyacrylamide gel electrophoresis and fluorography (see "Experimental Procedures"). Panel A, effect of GSH (0.3-3 mM) and S-methyl GSH (0.3-3 mM) alone on [3H]LTC4 labeling of MRP1. Panel B, inhibition of [3H]LTC4 labeling by estrone sulfate or estradiol sulfate (0.2-200 µM) alone and by the sulfates (0.2-20 µM) in the presence of 1 mM GSH. Panel C, effect of a combination of 1 mM S-methyl GSH with several concentrations of estrone sulfate (0.2-20 µM) on [3H]LTC4 labeling of MRP1. S-MeGSH, S-methyl GSH.

[3H]Estrone 3-Sulfate Transport in T5 Membrane Vesicles: Osmotic Sensitivity and Inhibition by MRP1-specific mAbs-- To determine whether it was possible to detect ATP-dependent MRP1-mediated transport of the estrogen sulfates, we determined the rate of [3H]estrone 3-sulfate (300 nM) uptake using T5 membrane vesicles. The rate of ATP-dependent uptake of estrone 3-sulfate was very low (5-6 pmol mg-1 protein min-1). However, an approximate 10-fold increase in the rate of transport was observed when 1 mM GSH was present (Fig. 3A). GSH-stimulated transport was linear for up to 60 s at a rate of ~60 pmol mg-1 protein min-1 with an initial concentration of 300 nM estrone 3-sulfate. In the presence of 4 mM AMP and 1 mM GSH, estrone 3-sulfate uptake by the vesicles was 2-4 pmol mg-1 protein min-1. ATP-dependent and GSH-stimulated estrone 3-sulfate transport was not detected with membrane vesicles prepared from vector-transfected HeLa C1 control cells (Fig. 3B).



View larger version (16K):
[in this window]
[in a new window]
 
Fig. 3.   Time course and kinetic parameters of [3H]estrone 3-sulfate uptake by membrane vesicles from MRP1-transfected HeLa cells. [3H]Estrone 3-sulfate uptake by membrane vesicles prepared from MRP1-transfected HeLa cells (T5) (panel A) or vector-transfected HeLa control cells (C1) (panel B) was determined at 37 °C in the presence (, open circle ) or absence (black-down-triangle , down-triangle) of 1 mM GSH for the times indicated. The initial concentration of [3H]estrone 3-sulfate was 300 nM with a specific activity of 17 Ci mmol-1. Closed symbols (, black-down-triangle ) indicate uptake in the presence of 4 mM ATP, and open symbols (open circle , down-triangle) represent uptake in the presence of 4 mM AMP. Panel C, [3H]estrone sulfate uptake by T5 vesicles was measured at estrone sulfate concentrations ranging from 125 nM to 16 µM for 1 min at 37 °C in the presence of 4 mM ATP and 1 mM GSH. Kinetic parameters were determined from nonlinear regression analysis. The calculated Km and Vmax for GSH-stimulated ATP-dependent [3H]estrone sulfate uptake were 0.73 ± 0.17 µM and 440 ± 27 pmol mg-1 min-1, respectively. The inset shows Eadie-Hofstee transformation of the data. Data points are the means (± S.E.) of triplicate determinations in a typical experiment.

To confirm that vesicle-associated estrone sulfate was indicative of transport into the vesicle lumen, rather than surface or intramembrane binding, we determined the effect of increasing extravesicular osmolarity. As expected for true transport, the amount of vesicle-associated [3H]estrone sulfate decreased with increasing concentrations of sucrose extrapolating to zero at infinite osmolarity (Fig. 4A).



View larger version (20K):
[in this window]
[in a new window]
 
Fig. 4.   Osmotic sensitivity and MRP1-specific mAbs inhibition of GSH-stimulated [3H]estrone sulfate transport by T5 membrane vesicles. Panel A, T5 membrane vesicles were preincubated on ice for 10 min in transport buffer containing sucrose (0.25-1 M). [3H]Estrone sulfate uptake was measured at 37 °C for 1 min in the presence of a combination of 1 mM GSH and 4 mM ATP (black-triangle) or 4 mM AMP (triangle ). Panel B, T5 membrane vesicles were preincubated on ice for 1 h with the indicated mAbs (10 µg ml-1). [3H]Estrone sulfate uptake was then measured at 37 °C for 1 min in the presence of 4 mM ATP and 1 mM GSH. Data points in both panels are means (± S.E.) of triplicate determinations in a typical experiment.

To confirm that transport was MRP1-mediated, we used previously characterized conformation-dependent MRP1-specific mAbs, which have been shown to inhibit MRP1-mediated transport of LTC4 and other MRP1 substrates (8-10, 26, 28, 32). As observed for other MRP1 substrates, three mAbs that recognize distinct conformation-dependent epitopes in the first (mAbs QCRL-2 and QCRL-3) and second (mAb QCRL-4) nucleotide-binding domains of MRP1 (26) completely inhibited ATP-dependent and GSH-stimulated estrone sulfate transport by T5 vesicles (Fig. 4B). In contrast, mAb QCRL-1, which recognizes a linear epitope in the linker region of MRP1(33), had no inhibitory effect.

To determine the kinetic parameters of estrone sulfate transport and the effect of GSH, rates of ATP-dependent uptake in the presence and absence of 1 mM GSH were determined at several concentrations of estrone 3-sulfate (125 nM to 16 µM) to obtain Km and Vmax values (Fig. 3C). A nonlinear regression analysis of the data yielded an apparent Km of 0.73 ± 0.17 µM for estrone 3-sulfate and a Vmax of 440 ± 27 pmol mg-1 protein min-1 in the presence of GSH, and an apparent Km of 4.2 ± 1.1 µM for estrone 3-sulfate and a Vmax of 107 ± 10 pmol mg-1 protein min-1 in its absence. The inset shows an Eadie-Hofstee transformation of the data (Fig. 3C).

When the nonreducing S-methyl GSH was used in place of GSH, 1 mM S-methyl GSH stimulated estrone 3-sulfate uptake by T5 membrane vesicles, somewhat more effectively than the same concentration of GSH (Fig. 5A). In contrast, the sulfhydryl reducing agents DTT (10 mM) and 2-mercaptoethanol (5 mM) and oxidized glutathione GSSG (0.05 mM) had no effect on estrone 3-sulfate transport. Since S-methyl GSH appeared to be a more potent stimulator of estrone sulfate transport than GSH, rates of transport were determined as a function of GSH or S-methyl GSH concentration (Fig. 5B). Both compounds exhibited a similar concentration dependence with 50% of maximal stimulation being observed at a concentration of ~0.5 mM. However, the maximal rate of estrone sulfate transport obtained with S-methyl GSH was ~2.5-fold greater than with GSH itself.



View larger version (21K):
[in this window]
[in a new window]
 
Fig. 5.   Effect of S-methyl GSH, sulfhydryl reducing agents, and GSSG on [3H]estrone 3-sulfate transport by MRP1-enriched T5 membrane vesicles. Panel A, ATP-dependent [3H]estrone 3-sulfate uptake was determined at 37 °C for 1 min in the presence of reducing agents (1 mM GSH, 5 mM 2-mercaptoethanol, or 10 mM DTT) or GSH derivatives (1 mM S-methyl GSH, 0.05 mM GSSG). The initial concentration of [3H]estrone 3-sulfate was 300 nM. Control (Con) shows uptake in the presence of 4 mM ATP alone, whereas other bars represent uptake in the presence of 4 mM ATP and one of the indicated agents. Bars represent the means (± S.E.) of triplicate determinations in a typical experiment. S-MeGSH, S-methyl GSH; 2-ME, 2-mercaptoethanol; GSSG, glutathione disulfide. Panel B, ATP-dependent [3H]estrone 3-sulfate uptake was determined at various concentrations of GSH () and S-methyl GSH (black-triangle) ranging from 31 µM to 4 mM for 1 min at 37 °C in the presence of a fixed initial concentration of [3H]estrone 3-sulfate (300 nM). Data points are means (± S.E.) of triplicate determinations in a typical experiment.

Inhibition of Estrone 3-Sulfate Transport by LTC4-- Since we found that estrogen sulfates competitively inhibited MRP1-mediated [3H]LTC4 transport in the presence of GSH, we determined whether the reverse was also true. Thus, the ability of LTC4 to inhibit [3H]estrone 3-sulfate transport by MRP1 was examined in T5 vesicles. GSH-enhanced estrone 3-sulfate uptake was inhibited by LTC4 in a dose-dependent manner (Fig. 6A). An Eadie-Hofstee plot of estrone 3-sulfate uptake in the presence of 0.2 µM LTC4 indicated that the inhibition was competitive, with an apparent Ki (LTC4) of 0.2 µM (Fig. 6B).



View larger version (22K):
[in this window]
[in a new window]
 
Fig. 6.   Inhibition by LTC4 of ATP-dependent and GSH-enhanced [3H]estrone 3-sulfate transport. Panel A, [3H]estrone 3-sulfate uptake by T5 membrane vesicles was determined at a fixed substrate concentration (300 nM) and various concentrations of LTC4 (5-1000 nM) for 1 min at 37 °C in the presence of 4 mM ATP and 1 mM GSH. Results are expressed as a percentage of the control value obtained in the absence of LTC4. The control uptake rate was 76 pmol mg-1 min-1, and each data point is the mean (± S.E.) of triplicate determinations in a single experiment. Panel B, ATP-dependent and GSH-enhanced [3H]estrone 3-sulfate uptake by T5 membrane vesicles was determined at various substrate concentrations (0.125-16 µM) in the absence (open circle ) or presence () of 200 nM LTC4 for 1 min at 37 °C. ATP (4 mM) and GSH (1 mM) were present in all the assays. Eadie-Hofstee plots were generated to show that LTC4 competitively inhibited GSH-enhanced estrone sulfate transport. In the absence or presence of 200 nM LTC4, the values of Km for estrone sulfate were 2.1 ± 0.2 µM and 4.8 ± 0.6 µM, whereas those of Vmax were 959 ± 60 pmol mg-1 min-1 and 823 ± 76 pmol mg-1 min-1. The apparent Ki for LTC4 was 160 nM. Data points are the means (± S.E.) of triplicate determinations in a single experiment.

Effect of Sulfated Estrogens on MRP1-mediated [3H]GSH Transport-- Previous studies of the GSH stimulated transport of the unconjugated xenobiotic vincristine revealed a reciprocal stimulation of GSH transport by the drug, suggesting a cotransport mechanism (10). In addition, verapamil was shown to markedly stimulate GSH transport by MRP1, but in this case no transport of verapamil could be detected (28). Consequently, we examined the ability of the estrogen sulfates to stimulate GSH transport using verapamil as a positive control. As expected, verapamil at 100 µM significantly enhanced GSH transport by about 3-fold. In the first set of experiments, 80 nCi of [3H]GSH was used in each reaction and no stimulation of GSH transport was observed with either estrogen sulfate at 0.2 and 2 µM. A modest stimulation (25%) was observed at 20 µM but only with estrone sulfate (Fig. 7A). In a second set of experiments, the amount of [3H]GSH was increased to 288 nCi/reaction to obtain a higher sensitivity of the transport assay. The modest stimulation of GSH transport by estrone sulfate was also detected at the concentration of 100 µM. However, addition of 100 µM estradiol sulfate inhibited rather than enhanced the low basal level of ATP-dependent [3H]GSH transport, which was ~25-30 pmol mg-1 min-1 at an initial concentration of 100 µM (Fig. 7B). This rate is approximately equivalent to the rate of [3H]estrone sulfate uptake in the presence of 100 µM GSH. To determine whether the basal level of ATP-dependent GSH transport observed with vesicles from MRP1 transfected cells was MRP1-mediated, we also examined the rate of ATP-dependent GSH transport by vesicles from HeLa C1 cells transfected with an empty vector and the ability of the MRP1 mAb QCRL-3 to inhibit transport. The rate of [3H]GSH transport by C1 vesicles was less than 5 pmol mg-1 min-1, and basal GSH transport by T5 vesicles was completely inhibited by QCRL-3 at 10 µg ml-1.



View larger version (25K):
[in this window]
[in a new window]
 
Fig. 7.   Effect of estrogen sulfates on [3H]GSH uptake by T5 membrane vesicles. Panel A, membrane vesicles (22 µg of protein) were incubated with 100 µM [3H]GSH (80 nCi/reaction) for 20 min at 37 °C in the presence of 5 mM DTT, 4 mM ATP, and the indicated concentrations (0.2-20 µM) of estrone 3-sulfate (E1S) or estradiol 3-sulfate (E2S). Verapamil (VRP, 100 µM) was used as a positive control stimulating MRP1-mediated GSH transport. Control (CON) represents ATP-dependent GSH transport in the absence of a second substrate. All data were corrected by subtracting [3H]GSH uptake in the presence of 4 mM AMP, and bars represent the means (± S.E.) of triplicate determinations in a single experiment. Panel B, experimental conditions were the same as above except that the amount of [3H] GSH was increased to 288 nCi/reaction. Control (CON) represents ATP-dependent GSH transport in the absence of a second substrate. Estrone 3-sulfate (E1S) and estradiol 3-sulfate (E2S) were added to 100 µM. All data were corrected by subtracting [3H] GSH uptake in the presence of 4 mM AMP, and bars represent the means (± S.E.) of triplicate determinations in a single experiment.

[3H]Estradiol Sulfate Accumulation in Intact HEK Cells Transiently Expressing est or est plus MRP1-- To determine whether the MRP1-mediated estrogen sulfate transport observed in vitro with membrane vesicles could also be detected in intact cells. HEK cells were transfected with pCDNA3-est alone and with pCEBV7-MRP1 together. The production and accumulation of [3H]estradiol sulfate in the est-transfected cells was then determined and compared with untransfected control cells, and with cells coexpressing est and MRP1. EST specifically catalyzes estrogen sulfation, and the identities of the products have been confirmed previously by high performance liquid chromatography to be estrogen 3-sulfates (31). Thus, an increased accumulation of tritium in the est-transfected cells incubated with [3H]estradiol reflects the accumulation of [3H]estradiol 3-sulfate, which unlike estradiol does not readily diffuse across the plasma membrane. Cytosolic extracts were also prepared from control and transfected cells and assayed directly for est activity as described previously (29, 31). The level of est activity obtained with extracts from cells transfected with either the est vector alone or cotransfected with the MRP1 vector were ~10-fold higher than in control cells. Cotransfection with the MRP1 vector had no detectable effect on the levels of EST activity (data not shown). As shown in Fig. 8, over a 20-min period, cells transfected with the EST vector accumulated ~2.5-fold more tritium than control cells and cotransfection with the MRP1 vector decreased this accumulation to a level that was only 50% higher than the controls. This decrease was statistically significant (p < 0.01, unpaired t test) (Fig. 8), consistent with an MRP1-mediated efflux of sulfated estrogen from the intact cells.



View larger version (19K):
[in this window]
[in a new window]
 
Fig. 8.   [3H]Estradiol sulfate accumulation by intact HEK cells transiently expressing est or est and MRP1. Untransfected control HEK cells and those transfected with the expression vector pCDNA3 containing est cDNA alone or in combination with pCEBV7-MRP1 for 66 h were harvested and incubated with 500 nM [3H]estradiol in serum-free DMEM at 37 °C for 20 min. [3H]Estradiol sulfate accumulation was then determined as described under "Experimental Procedures." Bars represent means (± S.E.) of triplicate determinations in a single experiment. *, p < 0.01 when compared with untransfected control cells; **, p < 0.01 when compared with the cells transfected with pCDNA3-est alone. The other half of aliquots of suspended cells were sonicated to prepare cytosolic proteins for est activity assay. An ~10-fold increase in the activity was found in the est-transfected cells, and MRP1 expression did not affect the activity.



    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Our data derived from studies with MRP1-enriched membrane vesicles and intact cells demonstrate that estrone and estradiol 3-sulfates are potential endogenous substrates for MRP1. The in vitro experiments, in which ATP-dependent transport of [3H]estrone sulfate was examined directly using plasma membrane vesicles from MRP1-transfected cells, confirmed that the conjugated estrogen is an MRP1 substrate and also revealed that a physiological concentration of GSH is required for its efficient transport. Direct demonstration of MRP1-mediated estrogen sulfate efflux from intact cells was precluded by the fact that the hydrophilic conjugates enter intact cells very poorly. Consequently, it was necessary to produce the estradiol 3-sulfate intracellularly by conjugation of [3H]estradiol. This was accomplished by using short term transfection to express est in HEK cells in the presence and absence of MRP1. The results demonstrated that the presence of MRP1 significantly decreased accumulation of the water-soluble estrogen conjugate produced by est.

The Km value (0.73 µM) for MRP1-mediated and GSH-enhanced estrone sulfate transport is comparable with that for organic anion transporter 3 (OAT3)- or organic anion transporter 4 (OAT4)-mediated transport of estrone sulfate (34, 35). However, these latter transporters have a more restricted tissue distribution than MRP1/mrp1 and are involved in the uptake rather than efflux of organic anions. The relatively high coexpression of MRP1/mrp1 with EST in Leydig cells suggests that MRP1 is likely to be involved in estrogen sulfate efflux from the testis. Since estrone sulfate can be converted back into estrone by estrogen sulfatase, efficient removal of estrone sulfate by an export pump is expected to be important for maintenance of low estrogen levels in organs such as the testis. Studies of mrp1-/- mice treated with etoposide phosphate strongly suggest that mrp1 may also protect the testis from exposure to cytotoxic xenobiotics (17). In addition, the recent report that EST is able to sulfate environmental estrogens, such as bis-, 4-octyl-, and p-nonylphenols, raises the possibility that MRP1 or related proteins could play a role in the cellular elimination of the conjugates of these estrogenic compounds (36).

The requirement of GSH for efficient transport of the sulfated estrogen provides the first example of GSH-enhanced transport of a conjugated endogenous substrate by MRP1. Previous studies have shown that GSH is required for the transport of some xenobiotics including unmodified chemotherapeutic agents such as vincristine (8-10), daunorubicin (9, 11) and aflatoxin B1 (32), and enhances transport of etoposide conjugated with glucuronate (37). GSH has been reported recently to stimulate transport of [3H]luteolin 7-O-diglucuronyl-4'-O-glucuronide in plant leaves, but the transporter involved has not been characterized structurally. However, it appears functionally to be a membrane-potential sensitive member of the ABC superfamily (38).

We have previously proposed that MRP1 contains a bipartite site to which the hydrophobic and anionic moieties of its conjugated substrates bind (8). Studies of the GSH-stimulated transport of vincristine, and the influence of GSH on the ability of vincristine to compete for LTC4 transport by MRP1, indicate that GSH not only increases the Vmax for the drug but also the affinity with which it interacts with the protein, as reflected by an approximate 20-fold increase in its inhibitory potency. These studies also indicated that vincristine reciprocally increases the affinity of MRP1 for GSH (10). The data suggest that initial low affinity binding of either GSH or drug by MRP1 induces a conformational change in the protein such that high affinity binding of the cotransported substrate can occur. In this respect, the model differs from the two-site model proposed by Borst et al. (39) in which the protein is envisaged to have two binding sites: one that has a relatively high affinity for drug and low affinity for GSH and another with high affinity for GSH and low affinity for drug (39). Although this model may explain the ability of drug and GSH to reciprocally stimulate cotransport, it is difficult to explain why GSH markedly increases the ability of drug to competitively inhibit transport of high affinity, conjugated substrates such as LTC4. Consistent with the existence of a low affinity site for GSH alone, our photoaffinity experiments with [3H]LTC4 indicate that GSH and S-methyl GSH decrease [3H]LTC4 labeling of MRP1 in a concentration-dependent manner in the millimolar range, suggesting that the binding sites for LTC4 encompass a low affinity site to which GSH (or S-methyl GSH) can bind.

Recent studies of drug binding and transport by the bacterial, homodimeric ABC multidrug resistance protein, Lmra, suggest positive cooperativity between allosterically linked low and high affinity substrate binding sites (40). A "two-cylinder engine" model, which embodies the alternating catalytic sites model proposed by Senior et al. (41), has been proposed in which the transport of drug from a high affinity intracellular site to a low affinity extracellular site on the same subunit of the homodimer is driven by the alternating hydrolysis of ATP at one or the other nucleotide binding domain. Thus, the two subunits cycle with respect to exposure of high or low affinity sites (40).

The evidence for positive cooperativity is based in part on the observation that two substrates that compete for transport at high concentrations reciprocally stimulate transport of each other at lower concentrations. Unlike the bacterial homodimeric transporters and transporters such as P-glycoprotein, the nucleotide binding domains of the MRP-related proteins are relatively divergent. Evidence to date suggests that they are also not functionally equivalent and may not alternate catalytically (42). Similarly, there is no evidence of primary structure conservation between the NH2 and COOH-proximal membrane-spanning domains of MRP1. However, we have consistently observed that low concentrations of the estrogen sulfates in the absence of GSH stimulate LTC4 transport and binding, as evidenced by photocross-linking studies, while they compete at higher concentrations. Thus, the data are also consistent with the existence of interacting binding sites being present on MRP1. However, since both the estrogen sulfates and LTC4 are relatively hydrophilic and the duration of transport assays is extremely short, the stimulation observed suggests that the sites are accessible from the cytoplasmic face of the membrane. In addition, the stimulation of binding occurs in the complete absence of nucleotide, indicating that if allosteric changes in structure occur following initial interaction with substrate, they do not require the binding and/or hydrolysis of ATP.

In some respects, the results we have obtained in the present study with estrone sulfate are similar to previous observations on the effect of GSH on rate of transport and apparent binding affinity of unmodified hydrophobic substrates such as vincristine, despite the fact that the compound is conjugated. However, in the case of vincristine, aflatoxin B1, and daunorubicin, it has not been possible to determine kinetic parameters of transport in the absence of GSH. Our data demonstrate that GSH decreases the Km for estrone sulfate from 4.2 to 0.73 µM and increases Vmax from 107 to 440 pmol min-1 mg protein-1. In addition, GSH also markedly enhanced the ability of estrone sulfate to inhibit photolabeling of MRP1 with LTC4. In these experiments, the GSH-enhanced inhibitory potency of estrone sulfate was obtained in the absence of ATP, indicating that any induced change in affinity for the conjugated estrogen occurs without a requirement for either nucleotide binding or hydrolysis.

Earlier studies with conjugated estrogens indicated that E217beta G could compete for LTC4 binding and transport by MRP1 while estrogens conjugated with glucuronide at the 3 position of the A-ring are very poor inhibitors (5). These studies also revealed that a change in site of glucuronidation from the 17beta to 16alpha position on the D-ring markedly decreased the affinity for the protein, as judged by the difference between the Ki values for E317beta G (1.4 µM) and E316alpha G (45 µM) as inhibitors of E217beta G transport. Taken together, the data indicate that strict structural requirements with respect to the site of glucuronidation of the steroid nucleus must be met to interact with MRP1 as a substrate or competitive inhibitor. Sulfation at the 3-position of the A-ring of E217beta G had little or no effect on its ability to compete for transport, implying that the presence of the sulfate group neither precluded nor enhanced interaction with the protein. In contrast, the conjugated bile salt glycolithocholate 3-sulfate was an effective inhibitor of E217beta G transport when compared with bile salts that were not conjugated at this position of the A-ring. This is consistent with the possibility that sulfation of the A-ring, in the absence of additional anionic conjugation, might enhance interaction with MRP1. A low level of transport of estrone sulfate could be detected in the absence of GSH, suggesting that sulfation resulted in the formation of a relatively low affinity, low capacity substrate in which the sulfate presumably does not prevent GSH from interacting with the protein, either because it binds to a different site or because it interacts only weakly with the GSH binding site. This latter possibility would be consistent with the inhibition of basal MRP1-mediated GSH transport by HeLa T5 vesicles observed at high concentrations of estradiol sulfate. However, the GSH has no effect on the inhibitory potency of other A-ring conjugates, such as E23beta G or on the transport of E217beta G, or estradiol itself (data not shown). Thus with respect to stimulation of transport by MRP1, it remains difficult to predict which conjugated or nonconjugated compounds might be affected by the presence of GSH.

It has been observed that GSH levels are increased in some tissues of mrp knockout mice (15) and decreased in drug-selected or transfected cells that overexpress MRP1 (12, 13), suggesting that MRP1 might efflux GSH either alone or via cotransport with currently unidentified, endogenous substrates. The stimulation of estrogen sulfate transport by GSH suggested that these compounds might be candidates for such substrates. Thus far, vesicle transport studies have provided strong evidence for cotransport of GSH with some xenobiotics (15, 10). However, in other cases, it has not been possible to detect a xenobiotic-dependent stimulation of GSH transport (10, 11). In addition, we have shown that some compounds, such as verapamil, can markedly stimulate MRP1-mediated GSH transport with no detectable net transport of the compound itself (28).

Despite the readily demonstrable GSH stimulation of estrone sulfate transport, we have not been able to detect reciprocal stimulation of GSH transport by the conjugated estrogen. No significant increase in GSH uptake by membrane vesicles could be detected in the presence of either estradiol or estrone sulfate over a 100-fold range of conjugated estrogen concentrations (0.2-20 µM). However, because of practical limitations, the highest concentration of [3H]GSH used in these studies is ~100 µM, and at this concentration the rate of estrone sulfate transport is ~25-30 pmol min-1 mg protein-1. Using [3H]GSH with a 7-fold higher specific activity than used in previous studies, we were able to detect a low but significant rate of ATP-dependent, MRP1-mediated GSH transport in the absence of a second substrate. This rate of basal GSH transport was approximately equivalent to the rate of estrone sulfate transport under the experimental conditions used. This leaves open the possibility that the "basal" rate of GSH transport by the protein is adequate under the experimental conditions to support cotransport of some substrates. However, this would imply that the interaction of substrates such as the estrogen sulfates, in contrast to compounds like verapamil, does not significantly affect the binding and transport of GSH. These studies expand the range of potential MRP1 substrates that require GSH for efficient transport to include certain hydrophilic anionic as well as previously identified hydrophobic, unconjugated compounds.


    ACKNOWLEDGEMENTS

We thank our colleagues Drs. Q. Mao and W. Qiu for providing membrane vesicles for initial experiments.


    FOOTNOTES

* This work was supported by grants from Eli Lilly and Co. and the National Cancer Institute of Canada with funds from the Terry Fox Run.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Senior scientist of Cancer Care Ontario.

|| Stauffer research professor of Queen's University. To whom correspondence should be addressed: Cancer Research Laboratories, Botterell Hall, Queen's University, Kingston, Ontario, Canada K7L 3N6. Tel.: 613-533-2981; Fax: 613-533-6830; E-mail: deeleyr@post.queensu.ca.

Published, JBC Papers in Press, December 1, 2000, DOI 10.1074/jbc.M008251200

2 Y. Qian, X. Sun, X. Li, and W. Song, submitted for publication.


    ABBREVIATIONS

The abbreviations used are: MRP, multidrug resistance protein; ABC, ATP-binding cassette; LTC4, leukotriene C4; E217beta G, 17beta -estradiol-17beta -D-glucuronide; E23beta G, 17beta -estradiol-3beta -D-glucuronide; E316alpha G, 16alpha ,17beta -estriol 16beta -D-glucuronide; GSH, reduced glutathione; GSSG, glutathione disulfide; DTT, dithiothreitol; mAb, monoclonal antibody; EST, estrogen sulfotransferase; DMEM, Dulbecco's modified Eagle's medium.


    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES


1. Cole, S. P. C., Bhardwaj, G., Gerlach, J. H., Mackie, J. E., Grant, C. E., Almquist, K. C., Stewart, A. J., Kurz, E. U., Duncan, A. M., and Deeley, R. G. (1992) Science 258, 1650-1654[Medline] [Order article via Infotrieve]
2. Hipfner, D. R., Deeley, R. G., and Cole, S. P. C. (1999) Biochim. Biophys. Acta 1461, 359-376[Medline] [Order article via Infotrieve]
3. Leier, I., Jedlitschky, G., Buchholz, U., Cole, S. P. C., Deeley, R. G., and Keppler, D. (1994) J. Biol. Chem. 269, 27807-27810[Abstract/Free Full Text]
4. Muller, M., Meijer, C., Zaman, G. J., Borst, P., Scheper, R. J., Mulder, N. H., de Vries, E. G., and Jansen, P. L. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 13033-13037[Abstract/Free Full Text]
5. Loe, D. W., Almquist, K. C., Cole, S. P. C., and Deeley, R. G. (1996) J. Biol. Chem. 271, 9683-9689[Abstract/Free Full Text]
6. Jedlitschky, G., Leier, I., Buchholz, U., Barnouin, K., Kurz, G., and Keppler, D. (1996) Cancer Res. 56, 988-994[Abstract]
7. Keppler, D., Cui, Y., Konig, J., Leier, I., and Nies, A. (1999) Adv. Enzyme Regul. 39, 237-246[CrossRef][Medline] [Order article via Infotrieve]
8. Loe, D. W., Almquist, K. C., Deeley, R. G., and Cole, S. P. C. (1996) J. Biol. Chem. 271, 9675-9682[Abstract/Free Full Text]
9. Renes, J., de Vries, E. G., Nienhuis, E. F., Jansen, P. L., and Muller, M. (1999) Br. J. Pharmacol. 126, 681-688[Abstract/Free Full Text]
10. Loe, D. W., Deeley, R. G., and Cole, S. P. C. (1998) Cancer Res. 58, 5130-5136[Abstract]
11. Ding, G. Y., Shen, T., and Center, M. S. (1999) Anticancer Res. 19, 3243-3248[Medline] [Order article via Infotrieve]
12. Cole, S. P. C., Downes, H. F., Mirski, S. E., and Clements, D. J. (1990) Mol. Pharmacol. 37, 192-197[Abstract]
13. Lautier, D., Canitrot, Y., Deeley, R. G., and Cole, S. P. C. (1996) Biochem. Pharmacol. 52, 967-977[CrossRef][Medline] [Order article via Infotrieve]
14. Zaman, G. J., Lankelma, J., van Tellingen, O., Beijnen, J., Dekker, H., Paulusma, C., R. P., Baas, F., and Borst, P. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 7690-7694[Abstract]
15. Rappa, G., Lorico, A., Flavell, R. A., and Sartorelli, A. C. (1997) Cancer Res. 57, 5232-5237[Abstract]
16. Flens, M. J., Zaman, G. J., van, d., V, Izquierdo, M. A., Schroeijers, A. B., Scheffer, G. L., van der, G., P., de Haas, M., Meijer, C. J., and Scheper, R. J. (1996) Am. J. Pathol. 148, 1237-1247[Abstract]
17. Wijnholds, J., Scheffer, G. L., van der Valk, M., van der Valk, P., Beijnen, J. H., Scheper, R. J., and Borst, P. (1998) J. Exp. Med. 188, 797-808[Abstract/Free Full Text]
18. Veri, J. P., Hermo, L., and Robaire, B. (1993) J. Androl. 14, 23-44[Abstract/Free Full Text]
19. Bauche, F., Fouchard, M. H., and Jegou, B. (1994) FEBS Lett. 349, 392-396[CrossRef][Medline] [Order article via Infotrieve]
20. Eddy, E. M., Washburn, T. F., Bunch, D. O., Goulding, E. H., Gladen, B. C., Lubahn, D. B., and Korach, K. S. (1996) Endocrinology 137, 4796-4805[Abstract]
21. Hess, R. A., Bunick, D., Lee, K. H., Bahr, J., Taylor, J. A., Korach, K. S., and Lubahn, D. B. (1997) Nature 390, 509-512[CrossRef][Medline] [Order article via Infotrieve]
22. Fisher, C. R., Graves, K. H., Parlow, A. F., and Simpson, E. R. (1998) Proc. Natl. Acad. Sci. U. S. A. 95, 6965-6970[Abstract/Free Full Text]
23. Song, W. C., Qian, Y. M., Sun, X., and Negishi, M. (1997) Endocrinology 138, 5006-5012[Abstract/Free Full Text]
24. Qian, Y. M., and Song, W. C. (1999) Endocrinology 140, 1048-1053[Abstract/Free Full Text]
25. Hipfner, D. R., Gauldie, S. D., Deeley, R. G., and Cole, S. P. C. (1994) Cancer Res. 54, 5788-5792[Abstract]
26. Hipfner, D. R., Mao, Q., Qiu, W., Leslie, E. M., Gao, M., Deeley, R. G., and Cole, S. P. C. (1999) J. Biol. Chem. 274, 15420-15426[Abstract/Free Full Text]
27. Grant, C. E., Valdimarsson, G., Hipfner, D. R., Almquist, K. C., Cole, S. P. C., and Deeley, R. G. (1994) Cancer Res. 54, 357-361[Abstract]
28. Loe, D. W., Deeley, R. G., and Cole, S. P. C. (2000) J. Pharmacol. Exp. Ther. 293, 530-538[Abstract/Free Full Text]
29. Qian, Y. M., Deng, C., and Song, W. C. (1998) J. Pharmacol. Exp. Ther. 286, 555-560[Abstract/Free Full Text]
30. Cole, S. P. C., Sparks, K. E., Fraser, K., Loe, D. W., Grant, C. E., Wilson, G. M., and Deeley, R. G. (1994) Cancer Res. 54, 5902-5910[Abstract]
31. Song, W. C., Moore, R., McLachlan, J. A., and Negishi, M. (1995) Endocrinology 136, 2477-2484[Abstract]
32. Loe, D. W., Stewart, R. K., Massey, T. E., Deeley, R. G., and Cole, S. P. C. (1997) Mol. Pharmacol. 51, 1034-1041[Abstract/Free Full Text]
33. Hipfner, D. R., Almquist, K. C., Stride, B. D., Deeley, R. G., and Cole, S. P. C. (1996) Cancer Res. 56, 3307-3314[Abstract]
34. Kusuhara, H., Sekine, T., Utsunomiya-Tate, N., Tsuda, M., Kojima, R., Cha, S. H., Sugiyama, Y., Kanai, Y., and Endou, H. (1999) J. Biol. Chem. 274, 13675-13680[Abstract/Free Full Text]
35. Cha, S. H., Sekine, T., Kusuhara, H., Yu, E., Kim, J. Y., Kim, D. K., Sugiyama, Y., Kanai, Y., and Endou, H. (2000) J. Biol. Chem. 275, 4507-4512[Abstract/Free Full Text]
36. Suiko, M., Sakakibara, Y., and Liu, M. C. (2000) Biochem. Biophys. Res. Commun. 267, 80-84[CrossRef][Medline] [Order article via Infotrieve]
37. Sakamoto, H., Hara, H., Hirano, K., and Adachi, T. (1999) Cancer Lett. 135, 113-119[CrossRef][Medline] [Order article via Infotrieve]
38. Klein, M., Martinoia, E., Hoffmann-Thoma, G., and Weissenbock, G. (2000) Plant J. 21, 289-304[CrossRef][Medline] [Order article via Infotrieve]
39. Borst, P., Evers, R., Kool, M., and Wijnholds, J. (1999) Biochim. Biophys. Acta 1461, 347-357[Medline] [Order article via Infotrieve]
40. van Veen, H. W., Margolles, A., Muller, M., Higgins, C. F., and Konings, W. N. (2000) EMBO J. 19, 2503-2514[Abstract/Free Full Text]
41. Senior, A. E., and Gadsby, D. C. (1997) Semin. Cancer Biol. 8, 143-150[CrossRef][Medline] [Order article via Infotrieve]
42. Gao, M., Cui, H. R., Loe, D. W., Grant, C. E., Almquist, K. C., Cole, S. P. C., and Deeley, R. G. (2000) J. Biol. Chem. 275, 13098-13108[Abstract/Free Full Text]


Copyright © 2001 by The American Society for Biochemistry and Molecular Biology, Inc.